瑞博生物-B：RBD5044于中国的II期临床试验默示许可

Core Viewpoint - RiboBio-B (06938) has received implied approval from the National Medical Products Administration of China for the Phase II clinical trial of its self-developed RBD5044 injection, which targets APOC3 and addresses complications related to hypertriglyceridemia [1] Group 1 - RBD5044 is a siRNA drug that specifically targets APOC3, a protein synthesized almost exclusively in the liver [1] - APOC3 plays a critical role in lipid metabolism, making RBD5044 a potential treatment option for managing dyslipidemia [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a new therapeutic choice in lipid management [1]